Project Grant R44CA295189
Award Date 9/22/25
Completion Date 8/31/27
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- This $1,340,987 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Koi Biotherapeutics Inc. aims to revolutionize chimeric antigen receptor (CAR) T-cell therapy by developing a novel CAR-enhancer platform to improve the functionality and persistence of CAR T-cells. The key products and services to be delivered under this 2-year project include: Optimization of dosing and timing for CAR-enhancer administration in a Phase I clinical trial to enhance...
- The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Lifengine Animal Health Laboratories Incorporated. The purpose of this Phase I grant is to demonstrate the feasibility of producing chimeric antigen receptor (CAR)-T cells that overexpress the transcription factor C-MYB to enhance their anti-tumor activity and limit functional exhaustion. Lifengine will leverage its proprietary GeneWeld gene editing platform to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,253,869.00 to Celdara Medical, LLC to develop CM-HZ01, a novel non-alpha IL-2 therapeutic for the treatment of metastatic melanoma. The funding will advance CM-HZ01 to Investigational New Drug (IND) status, with the goal of providing a best-in-class immunotherapy option for patients with limited effective treatment options for this deadly form of skin cancer. The project aims...
- This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
- The federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support a Phase 2 multi-center clinical trial of an innovative CD5 chimeric antigen receptor (CAR) T-cell therapy (MB-105) developed by March Biosciences Inc. for the treatment of relapsed/refractory T-cell lymphoma (R/R TCL). The $1,124,607 award, with a project period from July 1, 2025 to June 30, 2027, will fund the continued evaluation and advancement of this novel...
- The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $314,685 Project Grant to Persistence Therapeutics, Inc. under the Cancer Treatment Research program (CFDA 93.395). The grant supports the development of a novel CAR T cell therapy approach called "SynthNode" - an implantable device that mimics the function of a synthetic lymph node to produce potent, persistent CAR T cells for improved cancer treatment outcomes. The 1-year project aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,958 to Mabswitch Inc., a minority-owned small business, to assess the feasibility of regulating the activation, effector functions, and cytokine release of chimeric antigen receptor (CAR) T-cell therapies. The project aims to develop a "switchable affinity CAR" (SAEFCAR) that can be controlled by an exogenously administered ligand, potentially mitigating the toxicity...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,444 Project Grant to Cancure LLC (DBA Canzx Biotherapeutics) to conduct a feasibility study of a novel NK and CD8 T cells stimulating agent. The project aims to develop a complex molecule that can be used as an additive during NK and antigen-specific CD8 T cell expansion to enable their superior efficacy in treating solid tumors. The key objectives are to address the challenges of persistence and...
- The federal Project Grant award for $400,000.00 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports the development of an innovative approach to point-of-care autologous chimeric antigen receptor (CAR)-T cell manufacturing. The project, awarded to Aerocytek, Inc., a self-certified small disadvantaged business in California, aims to leverage targeted microbubble-based technologies to streamline and overcome the challenges in integrating...